Cancer Deals Dominate 2011 Start-Up Partnerships.

By Amanda Micklus / Email the Author / START-UP January 2012, Vol. 17, No. 1
Valuation Watch / Word Count: 610 / Article # 2012900009

Executive Summary

Among the partnership trends of the year, three stood out: oncology compounds, a search for more certain exits and the role reversal of Big Pharma as out-licensers.

Purchase this Article

$35.00 Buy Now

For $35.00, purchase this 610-word article and receive immediate online access. 100% Satisfaction Guarantee.

Already a Subscriber?

Log in for complete access.

Questions?

Call Toll-Free (800) 332-2181 or +1 (908) 547-2159.

Log In

Email Address

Password

Remember Me

Forgot your password?

Don’t Have an Account?

If your employer has a site license, create your account to begin using it. Simply click ‘Create An Account’ button below to register now.

Otherwise, please explore our free content subscriptions.

Create an account

Enter the email address associated with your account and a temporary password will be sent to you.

Email Address

Need help? Contact us at (800) 332-2181, +1 (908) 547-2159, or custcare@elsevier.com

Email Article

* Required field

* To:

For multiple recipients, separate email addresses with a semi-colon.

* Your Name:

* Your Email:

Subject: Cancer Deals Dominate 2011 Start-Up Partnerships.

* Add a personalized message to your email:

Please Note: Only individuals with subscriptions to START-UP will be able to access the full article. All other readers will be directed to the abstract and may purchase the article.

or Cancel

Cancer Deals Dominate 2011 Start-Up Partnerships.

Executive Summary

Purchase this Article

Already a Subscriber?

Questions?

Related Articles: 3

Elsevier Business Intelligence Publications

Offers & Events

Topics Covered in this Article

Email Article